return equiti ttm
fourth-quart top-lin bottom-lin miss major phase
readout first half
monday februari market close gilead report fourth quarter full
year financi result exhibit revenu quarter billion
consensu estim billion hiv franchis revenu came billion
beat consensu estim billion repres growth third
quarter world-wide hcv revenu million estim million
consensu million sequenti declin third quarter yescarta sale
million lower estim million consensu estim
million note fourth quarter hiv beat driven favor payer mix
strong uptak biktarvi inventori purchas hcv franchis miss larg
due competit outperform mavyret bottom line
non-gaap ep quarter estim consensu
full-year non-gaap ep estim consensu
miss non-gaap ep primarili due excess harvoni inventori result
shift demand epclusa higher invest million
impair anti-bmca cell therapi record fourth quarter
complet varianc analysi expect consensu actual result
quarter summar exhibit manag issu guidanc decreas
top line model continu recogn rel flat year
return growth
key catalyst phase pipelin catalyst includ
data first quarter would lead first nda file filgotinib rheumatoid
arthriti ra stellar stellar data first half selonsertib nash
discov first half descovi pre-exposur prophylaxi prep
data readout could move needl gilead continu trade one lowest
among large-cap comp continu hold long-term posit view gilead share
due strong hiv franchis growth hcv franchis stabil dividend yield
promis cell therapi field strong balanc sheet potenti consolid due
cheaper biotech valuat
gilead research-bas biotechnolog compani focus develop therapi treatment life-
threaten diseas gilead leader hiv/aid therapeut recent hcv also
larg product portfolio includ therapeut liver cardiovascular inflammatori respiratori diseas
upcom catalyst includ phase readout filgotinib selonsertib
first half estim billion billion peak sale
probabl success respect believ two agent
key return gilead growth phase readout highli impact
gilead share new strateg direct set incom ceo also serv
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
manag issu guidanc see slight declin revenu compar addit
increas oper expens due expand pipelin commerci hire due prepar potenti
launch selonsertib compani also see flat tax year-over-year incorpor manag guidanc
model detail chang estim non-gaap ep previous
top line product sale estim fall billion billion repres
decreas midpoint slight decreas larg attribut continu declin
hcv sale off-set grow hiv sale yescarta manag project hcv sale come
billion billion competit abbvi mavyret appear stabil end
market share reach close estim equilibrium continu ascrib matur market
share mavyret gilead franchis due mavyret simpl algorithm competit profil
long term expect gilead hcv sale continu steadi declin due competit updat
model fit within guidanc forecast hcv sale billion billion previous
project hcv sale billion potenti upsid estim could come sale hcv
franchis product china exhibit
roughli flat revenu growth upheld continu strength blockbust hiv franchis
expect grow manag expect hiv franchis continu driven
biktarvi prescrib regimen treatment-nav switch patient total hiv other-non-hcv
antivir sale grew driven continu uptak taf-bas regimen base
continu growth rate hiv franchis forecast sale hiv antivir billion
billion biktarvi b/f/taf approv februari mark compani eighth final
combin regimen develop hiv platform lifelong control hiv infect third full quarter
market biktarvi brought million volum come switch patient
came patient previous dolutegravir-contain regimen came genvoya patient
rapid rate adopt biktarvi exceed genvoya previous grab top spot launch
uptak among hiv regimen unlik genvoya requir pharmacokinet booster cobicistat biktarvi
need booster improv safeti profil posit biktarvi becom primari option
treatment-nav switch patient addit total hiv script volum also increas year-over-year
reflect gilead preemin posit field continu expect compani hiv franchis continu
hold absolut domin hiv market current market share grow
forecast sustain growth first next-gener taf-bas regimen begin lose
compani guid non-gaap expens billion sg expens billion-
billion total oper expens repres increas midpoint
increas sg estim billion billion within guidanc
base disappoint quarter lower yescarta sale estim manag guid
yescarta sale roughli million greater million recogn result
lower yescarta sale estim million million previous
maintain outperform rate fair valu estim exhibit model continu recogn
rel flat year return growth dcf analys hiv hcv franchis lead valuat
per share respect late stage asset expect read phase data valu filgotinib
per share probabl success rheumatoid arthriti probabl success ulcer
coliti crohn diseas valu selonsertib per share advanc nash probabl success
addit valu yescarta next-gener product candid per share includ per share net cash
year-end deriv fair valu estim gilead share
look key catalyst move needl return gilead top line growth data
second third three phase studi filgotinib rheumatoid arthriti ra
anticip first quarter could lead first regulatori file asset nash expect
phase ii data studi fxr agonist well data two phase studi inhibitor
selonsertib first half two phase studi evalu selonsertib monotherapi
bridg fibrosi compens cirrhosi respect stellar studi began screen patient
first quarter goal enrol patient trial co-primari endpoint studi
percent patient achiev least one stage improv fibrosi score without worsen nash
week event-fre surviv week secondari endpoint includ proport patient nash
resolut without worsen fibrosi variou time point proport patient progress cirrhosi
week current estim probabl success billion peak sale selonsertib note
phase ii studi selonsertib patient fibrosi regress demonstr
dose-depend manner small number patient selonsertib studi patient prior
phase studi data discov descovi prep anticip second quarter discov
random double-blind placebo-control studi primari outcom measur incid hiv infect per
person year patient enrol prep use continu grow unit state patient
fourth quarter cdc estim million peopl unit state could benefit prep
yescarta fourth full quarter market miss expect million book competit
continu intensifi novarti nv gilead race launch respect lead car-t
kymriah yescarta across transplant center unit state fourth quarter novarti book
million sale kymriah two approv indic pediatr acut lymphoblast leukemia
r/r diffus larg b-cell lymphoma dlbcl gilead achiev author center unit state
end januari first-mov advantag set base compani site geography-bas
strategi roughli patient current within reason distanc certifi transplant center
europ compani achiev author center germani franc plan author
total center
strateg develop deploy capit remain key goal new ceo look make mark
continu believ gilead provid long-term opportun valu growth dividend yield
robust share buy-back program manag reiter compani continu evalu strateg deal
priorit use capit invest long-term growth recent exemplifi collabor
hifibio tango scholar outperform view oncolog liver diseas
inflamm area high interest develop believ addit strateg acquisit could
take place near futur enhanc compani pipelin bolster growth
risk outperform thesi includ compani depend hiv franchis repres fundament
concentr risk investor magnitud speed declin hcv franchis continu pipelin expans
cellular therapi clinic risk filgotinib selonsertib phase studi pipelin asset
hcv product royalti contract total sg total oper interest expens incom expens pre-tax provis incom net net incom loss attribut non-controlling net incom attribut non- reconciliationcost good sold expens sg expens interest expens total non- adjust incom tax effect tax reform total non- adjust non- net incom attribut non- dividend per common weight averag share outstand weight averag share outstand compani report william blair scienc inc incom statement william blair
actualwb estimatespreadvarianceq/q growthy/i growthcon hcv hiv product cost expensescost good gener net incom attribut ep compani report william blair estimatescurr scienc inc current quarter varianc analysi dollar million except ep william blair
sourc compani report william blair estimatesexhibit scienc inc hcv global marketsourc compani report william blair estimatesexhibit scienc inc hiv franchis revenu regimen regimenstaf regimensatriplatruvadacompleraodefseydescovystribildgenvoyab/f/tafu patent expir date william blair
drugpeak sale stage ofdevelopmentestimatedlaunch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuehiv phase phase year-end present valu addit loss fair includ cost directli relat program abovesourc william blair estimatesexhibit scienc inc fair valu import disclosur
